{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:19:15Z","timestamp":1789265955706,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":721,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["1RO1FD003539"],"award-info":[{"award-number":["1RO1FD003539"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1111\/ajt.16121","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T22:41:07Z","timestamp":1591656067000},"page":"3609-3619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-0457","authenticated-orcid":false,"given":"Robin","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary W.","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-4279","authenticated-orcid":false,"given":"He","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1111\/ajt.16121_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant."},{"issue":"8","key":"10.1111\/ajt.16121_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med."},{"issue":"5 Pt 1","key":"10.1111\/ajt.16121_bib3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1600-6143.2006.01259.x","article-title":"A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression","volume":"6","author":"Larsen","year":"2006","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.16121_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant."},{"issue":"9","key":"10.1111\/ajt.16121_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.16121_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16121_bib7","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/15256","article-title":"Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance","volume":"5","author":"Li","year":"1999","journal-title":"Nat Med."},{"issue":"4","key":"10.1111\/ajt.16121_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1111\/ajt.16121_bib9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ajt.13613","article-title":"CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection","volume":"16","author":"Espinosa","year":"2016","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16121_bib10","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1111\/ajt.12937","article-title":"CD28 negative T cells: is their loss our gain?","volume":"14","author":"Mou","year":"2014","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16121_bib11","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.4049\/jimmunol.180.11.7203","article-title":"A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28\/CD154-independent rejection","volume":"180","author":"Ford","year":"2008","journal-title":"J Immunol."},{"issue":"1","key":"10.1111\/ajt.16121_bib12","first-page":"CD004759","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"9346","key":"10.1111\/ajt.16121_bib13","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(02)11606-0","article-title":"Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy","volume":"360","author":"Swanson","year":"2002","journal-title":"Lancet."},{"issue":"6","key":"10.1111\/ajt.16121_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16121_bib15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/15260","article-title":"Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance","volume":"5","author":"Wells","year":"1999","journal-title":"Nat Med."},{"issue":"7","key":"10.1111\/ajt.16121_bib16","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/j.1600-6143.2007.01842.x","article-title":"Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells","volume":"7","author":"Gao","year":"2007","journal-title":"Am J Transplant."},{"issue":"5","key":"10.1111\/ajt.16121_bib17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant."},{"issue":"Suppl 2","key":"10.1111\/ajt.16121_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ajt.15274","article-title":"OPTN\/SRTR 2017 annual data report: kidney","volume":"19","author":"Hart","year":"2019","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.16121_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MOT.0b013e32833b7916","article-title":"Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations","volume":"15","author":"Ford","year":"2010","journal-title":"Curr Opin Organ Transplant."},{"issue":"1","key":"10.1111\/ajt.16121_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-6143.2010.03317.x","article-title":"Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression","volume":"11","author":"Lo","year":"2011","journal-title":"Am J Transplant."},{"issue":"7","key":"10.1111\/ajt.16121_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.it.2009.03.013","article-title":"CD28(-) T cells: their role in the age-associated decline of immune function","volume":"30","author":"Weng","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1111\/ajt.16121_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.0105-2896.2005.00256.x","article-title":"CD28 extinction in human T cells: altered functions and the program of T-cell senescence","volume":"205","author":"Vallejo","year":"2005","journal-title":"Immunol Rev."},{"issue":"6","key":"10.1111\/ajt.16121_bib23","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.4049\/jimmunol.167.6.3231","article-title":"Down-regulation of CD28 expression by TNF-alpha","volume":"167","author":"Bryl","year":"2001","journal-title":"J Immunol."},{"issue":"7","key":"10.1111\/ajt.16121_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/intimm\/12.7.1005","article-title":"Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis","volume":"12","author":"Borthwick","year":"2000","journal-title":"Int Immunol."},{"issue":"11","key":"10.1111\/ajt.16121_bib25","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.4049\/jimmunol.177.11.7802","article-title":"Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines","volume":"177","author":"Chiu","year":"2006","journal-title":"J Immunol."},{"issue":"9","key":"10.1111\/ajt.16121_bib26","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/ajt.14350","article-title":"Increased pretransplant frequency of CD28(+) CD4(+) TEM predicts belatacept-resistant rejection in human renal transplant recipients","volume":"17","author":"Cortes-Cerisuelo","year":"2017","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.16121_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/ajt.13469","article-title":"Postdepletion lymphocyte reconstitution during belatacept and rapamycin treatment in kidney transplant recipients","volume":"16","author":"Xu","year":"2016","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.16121_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/ajt.15639","article-title":"B cell reconstitution following alemtuzumab induction under a belatacept-based maintenance regimen","volume":"20","author":"Xu","year":"2020","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.16121_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16121_bib30","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function","volume":"17","author":"Adams","year":"2017","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.16121_bib31","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/TXD.0000000000000579","article-title":"Open-label, randomized study of transition from tacrolimus to sirolimus immunosuppression in renal allograft recipients","volume":"2","author":"Tedesco-Silva","year":"2016","journal-title":"Transplant Direct."},{"issue":"8","key":"10.1111\/ajt.16121_bib32","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","article-title":"Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus","volume":"42","author":"Sanchez-Fructuoso","year":"2010","journal-title":"Transpl Proc."},{"issue":"3","key":"10.1111\/ajt.16121_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.trre.2011.05.002","article-title":"The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen","volume":"26","author":"Suwelack","year":"2012","journal-title":"Transplant Rev."},{"issue":"8","key":"10.1111\/ajt.16121_bib34","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.16121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.16121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.16121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522216426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522216426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.16121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:29:52Z","timestamp":1761629392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522216426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1600613522216426"],"URL":"https:\/\/doi.org\/10.1111\/ajt.16121","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.16121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}